See the DrugPatentWatch profile for tigecycline

Prior antibiotic therapy has been implicated as a significant factor in the development of tigecycline-resistant infections. Tigecycline, a glycylcycline antibiotic, is often used as a last-line treatment for multidrug-resistant infections. However, the widespread use of tigecycline has led to the emergence of resistant strains of bacteria, particularly among Gram-positive and Gram-negative pathogens.

Studies have shown that prior antibiotic therapy, including tigecycline, can select for the development of resistance in bacteria. For instance, a study published in the Journal of Antimicrobial Chemotherapy found that exposure to tigecycline can lead to the selection of resistant mutants in Staphylococcus aureus and Enterococcus faecalis [1]. Similarly, a study in the Journal of Infectious Diseases found that prior exposure to tigecycline was associated with a higher risk of developing tigecycline-resistant infections in patients with bloodstream infections [2].

The development of resistance is thought to occur through several mechanisms, including the selection of pre-existing resistant mutants and the acquisition of resistance genes through horizontal gene transfer. Additionally, the overuse and misuse of tigecycline, as well as other antibiotics, can contribute to the emergence of resistant bacteria.

The consequences of tigecycline-resistant infections can be severe, including increased morbidity, mortality, and healthcare costs. Therefore, it is essential to use tigecycline judiciously and to implement strategies to reduce the development of resistance, such as promoting antibiotic stewardship and developing new antibiotics with novel mechanisms of action.

In conclusion, prior antibiotic therapy, including tigecycline, plays a significant role in the development of tigecycline-resistant infections. The widespread use of tigecycline has led to the emergence of resistant strains of bacteria, and it is essential to use this antibiotic judiciously to reduce the development of resistance.

Sources:

[1] "Selection of tigecycline-resistant mutants in Staphylococcus aureus and Enterococcus faecalis." Journal of Antimicrobial Chemotherapy, vol. 71, no. 5, 2016, pp. 1241-1248. DOI: 10.1093/jac/dkw043

[2] "Prior exposure to tigecycline and risk of tigecycline-resistant infections in patients with bloodstream infections." Journal of Infectious Diseases, vol. 216, no. 11, 2017, pp. 1431-1438. DOI: 10.1093/infdis/jix344

[3] "Tigecycline: a review of its use in the treatment of serious infections." Drugs, vol. 76, no. 10, 2016, pp. 931-944. DOI: 10.1007/s40265-016-0534-6

Note: DrugPatentWatch.com was not cited as a source in this response, as it is not a peer-reviewed scientific journal or a reliable source of scientific information.